PCV60 Cost Effectiveness of Dabigatran Etexilate for Prevention of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation Patients in the Turkish Health Care …

S Kececioglu, P Ulus, F Cukadar - Value in Health, 2012 - valueinhealthjournal.com
Objectives To investigate the cost-effectiveness of dabigatran etexilate (dabigatran 150MG)
in the Turkish health care setting. Methods A model was constructed to assess the cost …
相关文章
[PDF] academia.edu

[PDF][PDF] COST EFFECTIVENESS OF DABIGATRAN ETEXILATE FOR PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN NONVALVULAR ATRIAL …

S Kececioglu, P Ulus, F Cukadar - academia.edu
OBJECTIVES: Since the required time horizon in a cost effectiveness decision model often
exceeds the evidence time horizon, numerous temporal uncertainties arise regarding model …

[引用][C] PCV60 Cost Effectiveness of Dabigatran Etexilate for Prevention of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation Patients in the Turkish …

S Kececioglu, P Ulus, F Cukadar - Value in Health, 2012 - infona.pl
PCV60 Cost Effectiveness of Dabigatran Etexilate for Prevention of Stroke and Systemic
Embolism in Nonvalvular Atrial Fibrillation Patients in the Turkish Health Care Setting × Close …
[PDF] core.ac.uk

[PDF][PDF] COST EFFECTIVENESS OF DABIGATRAN ETEXILATE FOR PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN NONVALVULAR ATRIAL …

S Kececioglu, P Ulus, F Cukadar - core.ac.uk
OBJECTIVES: Since the required time horizon in a cost effectiveness decision model often
exceeds the evidence time horizon, numerous temporal uncertainties arise regarding model …
[PDF] researchgate.net

[PDF][PDF] COST EFFECTIVENESS OF DABIGATRAN ETEXILATE FOR PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN NONVALVULAR ATRIAL …

S Kececioglu, P Ulus, F Cukadar - researchgate.net
OBJECTIVES: Since the required time horizon in a cost effectiveness decision model often
exceeds the evidence time horizon, numerous temporal uncertainties arise regarding model …
[PDF] core.ac.uk

[PDF][PDF] COST EFFECTIVENESS OF DABIGATRAN ETEXILATE FOR PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN NONVALVULAR ATRIAL …

S Kececioglu, P Ulus, F Cukadar - core.ac.uk
OBJECTIVES: Since the required time horizon in a cost effectiveness decision model often
exceeds the evidence time horizon, numerous temporal uncertainties arise regarding model …

[引用][C] PCV60 Cost Effectiveness of Dabigatran Etexilate for Prevention of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation Patients in the Turkish …

S Kececioglu, P Ulus, F Cukadar - Value in Health, 2012 - Elsevier